|Antibody Name: ||
SK2 (VH SGI | VL kV)
Sato, K., Ohtomo, T., Hirata, Y., Saito, H., Matsuura, T., Akimoto, T., Akamatsu, K-i., Koishihara, Y., Ohsugi, Y. and Tsuchiya, M.
"Humanization of an anti-human IL-6 mouse monoclonal antibody glycosylated in its heavy chain variable region"
Hum. Antibod. Hybridoma (1996) 7:175-183.
|Donor Antibody: ||
|Acceptor Antibody: ||
Human IgG1 | k
human IL-6 (epitopes: receptor binding site (I) and gp130 interaction domain
(II), this mAb probably recognises an epitope close to both sites).
Chugai Pharmaceutical Co. Ltd., Japan
Highest homology to VH SG II (DAW) and kI (REI). Modelled V regions plus
carbohydrate moiety on glycosylation site.
VH DAW | VL REI (as in Campath-1H).
All 6 VH and VL, Kabat Definition.
Affinity constants (Kd)(Kon/Koff) were measured by surface plasmon resonance
on BIAcore (Pharmacia) machine. The two versions of the light chain showed
good Ag-binding activity. However, the F71Y change gave better results in
functional (binding inhibition) assays.
Transient expression in cos-7 cells and stable CHO transformants.
N-glycosylation site at position 30:H (Canonical for CDR-H1, N instead
of usual S). Experiments with deglycosylated mAbs showed it did not
significantly influence Ag/Ab interaction (contrast with
|Clinical Indication: ||
Increased levels of IL-6 in sepsis, AIDS, rheumatoid arthritis and cardiac myxoma.
IL-6 is a growth factor for malignant cells in plasmacytoma/myeloma and mesangial glomerulonephritis.
It is an autocrine/paracrine factor in osteoclasts in Paget's disease.